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Background: Molecules taken up by olfactory and trigeminal nerve neurons directly access 
the brain by the nose-to-brain pathway. In situ-forming mucoadhesive gels would increase the 
residence time of intranasal material, favoring the nose-to-brain delivery. In this first approach, 
brain radioactivity after intranasal administration of 32P-small interference RNA (siRNA) 
  complexed with poly(amidoamine) G7 dendrimers (siRNA dendriplexes) within in situ-forming 
mucoadhesive gels, was determined.
Materials:  32P-siRNA dendriplexes were incorporated into in situ-forming mucoadhesive 
gels prepared by blending thermosensitive poloxamer (23% w/w) with mucoadhesive chitosan 
(1% w/w, PxChi) or carbopol (0.25% w/w, PxBCP). Rheological properties, radiolabel release 
profile, and local toxicity in rat nasal mucosa were determined. The best-suited formulation was 
intranasally administered to rats, and blood absorption and brain distribution of radioactivity 
were measured.
Results: The gelation temperature of both formulations was 23°C. The PxChi liquid showed 
non-Newtonian pseudoplastic behavior of high consistency and difficult manipulation, and the 
gel retained 100% of radiolabel after 150 minutes. The PxCBP liquid showed a Newtonian 
behavior of low viscosity and easy manipulation, while in the gel phase showed apparent vis-
cosity similar to that of the mucus but higher than that of aqueous solution. The gel released 
35% of radiolabel and the released material showed silencing activity in vitro. Three intranasal 
doses of dendriplexes in PxCBP gel did not damage the rat nasal mucosa. A combination of 
32P-siRNA complexation with dendrimers, incorporation of the dendriplexes into PxCBP gel, 
and administration of two intranasal doses was necessary to achieve higher brain radioactivity 
than that achieved by intravenous dendriplexes or intranasal naked siRNA.
Conclusion: The increased radioactivity within the olfactory bulb suggested that the 
  combination above mentioned favored the mediation of a direct brain delivery.
Keywords: nucleic acids, gel, dendrimers, mucosa, olfactory bulb
Introduction
While nasal delivery has probably been the most successful of the alternative 
  transmucosal routes as a portal of entry into the systemic circulation for substances that 
cannot be given orally,1 research into whether the intranasal route might deliver poten-
tially therapeutic amounts of large molecules such as proteins and nucleic acids to the 
central nervous system (CNS) was first described only a little over a decade ago.2–4 The 
delivery of most therapeutics to the brain parenchyma is impaired by the   blood–brain 
barrier (BBB). Together with a low rate of pinocytosis and the presence of efflux pumps 
(eg, P-glycoprotein), the BBB presents low paracellular   permeability, due to the tight 
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junctions between endothelial cells, which induce a high 
transendothelial electrical resistance (1500–2000 Ω ⋅ cm2 com-
pared to 3–30 Ω ⋅ cm2 across most peripheral   microvessels). 
Excepting the diffusion of lipid-soluble molecules of molecu-
lar weight lower than 400 Da, only glucose and amino acids 
internalized by carrier-mediated transport or insulin and 
transferrin internalized by receptor-mediated transport, gain 
entry to the CNS by the BBB.5
The direct delivery of intranasally administered mole  cules 
occurs by neuronal uptake and is a noninvasive and simpler 
alternative route than parenteral administration that bypasses 
the BBB, avoids fast systemic clearance, and limits potential 
secondary effects.6–8 Neuronal uptake can occur at the olfac-
tory or the trigeminal nerve systems, exposed at the olfactory 
and respiratory epitheliums of the nose, respectively. This 
makes the nose-to-brain pathway the most direct method for 
noninvasive entry into the brain. Direct delivery to the brain 
of small molecules and biologics such as proteins and gene 
vectors has now been documented in numerous animal and 
clinical studies.3,9,10 This pathway is presumably involved in 
the increased cerebrospinal fluid levels of molecules that do 
not cross the BBB, such as peptides melanocortin,4–10 and 
insulin11 in humans. Also intranasal delivery of oxytocin 
showed a wide range of effects on human behavior and may 
be of clinical benefit for social disorders such as anxiety, 
psychological stress, and autism.12,13
Although the potential of RNA interference-based thera-
pies against diseases affecting the CNS such as spinocerebel-
lar ataxias, Parkinson’s disease, Alzheimer’s disease, and 
brain tumors has been successfully revealed in vitro and on in 
vivo models,14 the BBB penetration of high molecular weight 
and negatively charged small interfering RNA (siRNA) is 
impaired. Because of this, the delivery of siRNA to the 
CNS has been mostly based on invasive administrations of 
naked or electrostatically complexed siRNA with cationic 
lipids or polymers. For instance intraventricular injection,15,16 
perilesional stereotactic injections,17 direct injection in the 
hippocampus18 or in the right striatum,19 convection-enhanced 
delivery,20 and local electroporation21 have been used to 
knock down different exogenous or endogenous genes. 
Other approaches less explored, that do not involve direct 
neuronal uptake, rely on the intravenous administration 
of siRNA or its complexes coupled to ligands targeted to 
receptors on the brain capillary endothelial cell, such as the 
transferrin receptor,22 the nicotinic acetylcholine receptor,23 
the low-density lipoprotein receptor,24,25 or the rabies virus 
glycoprotein peptide.26 One research project has shown the 
presence of fluorescein isothiocyanate-labeled siRNA and 
the reduced expression of αB-crystallin in the olfactory 
bulb after intranasal administration of siRNA/commercial 
cationic lipid complexes.27
We have previously shown that degradation of naked 
siRNA by RNAses can be reduced and its endocytic uptake 
increased after electrostatic complexation with cationic den-
drimers.28 We showed that electrostatic complexes between 
siRNA/poly(amidoamine) generation 7   dendrimers (G7) 
(siRNA dendriplexes) prepared in low ionic strength medium 
inhibited the expression of enhanced green   fluorescent pro-
tein both in human glioblastoma cells and in macrophages 
in vitro.
In this work, we compared the brain radioactivity after 
intranasal administration of radiolabeled siRNA dendriplexes 
within in situ-forming mucoadhesive gel, with that after 
intranasal naked siRNA in gel, and intravenous siRNA den-
driplexes. The route and formulation that provide the highest 
brain radioactivity would be the most likely to achieve brain 
silencing. In humans, the olfactory epithelium is located in 
the roof of the nasal cavity, making access by powders or 
instillations difficult.29 Hence to prevent drainage from the 
site of application and to overcome the nasal mucociliary 
clearance, siRNA dendriplexes were included within in 
situ-forming mucoadhesive gels. The rheological properties 
of blends of the thermosensitive poloxamer (23% w/w) with 
the mucoadhesive chitosan (1% w/w) or carbopol (0.25% 
w/w) were determined in the absence or presence of siRNA 
dendriplexes both in liquid and gel states. After testing the 
release from gels, in vitro silencing activity, and toxicity in 
nasal mucosa, the best-suited formulation was intranasally 
administered to rats. After one or two intranasal doses, the 
regional brain distributions and blood levels of radioactivity 
were determined.
Materials and methods
Materials
Poly(amidoamine) G7 dendrimers (MW: 116488.71 g/mol, 
512 amine end groups) and benzethonium hydroxide 1M 
were purchased from Sigma-Aldrich, MO. Enhanced green 
fluorescent protein siRNA sense sequence 5-GCACGAC-
UUCUUCAAGUCCdTdT-3 and 5-GGACUUGAAGAA-
GUCGUGCdTdT-3 (antisense) was synthesized by Bioneer 
and purified by high-performance liquid chromatography. 
Lipofectamine™ 2000 was obtained from Gibco, (Gibco 
Life Technologies, New York, NY) T4 polynucleotide kinase 
was from Thermo Scientific (Waltham, MA). Scintillation 
cocktail Optiphase “HiSafe” 3 and γ-[32P]-ATP 3000 Ci/
mmol, 3.33 µM were from PerkinElmer (Waltham, MA). 
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Ketamina 50 was from Holliday-Scott SA (Buenos Aires, 
Argentina) and acepromazine Seda-T from Zoovet Labora-
tories (Santa Fe,   Argentina). Polyacrilic acid (carbopol 974P 
NF) was from Lubrizol (Wickliffe, OH), poloxamer 407 
(Pluronic® F127) from BASF, (Buenos Aires, Argentina), and 
  Protasan UP CL113 (chitosan with 75%–90% of deacetyla-
tion degree, molecular weight: 50,000–150,000 g/mol) was 
from   NovaMatrix, Sandvika, Norway. All other chemicals 
and reagents were of analytical grade from Anedra (San 
  Fernando, Argentina).
siRNA dendriplexes and lipoplexes 
preparation
siRNA dendriplexes were prepared as stated in Perez et al.30 
Briefly, an aliquot of G7 from methanol stock was diluted in 
10 mM Tris-HCl pH 7.4 buffer (Tris-HCl buffer) and siRNA 
was added to give a 10/1 (N/P, the available amino groups 
in dendrimer to the RNA phosphate groups ratio) ratio. The 
mixture was incubated 20 minutes at room temperature prior 
to use. SiRNA lipoplexes were prepared according to the 
manufacturer’s instructions; an aliquot of Lipofectamine 
2000 was diluted in Tris-HCl buffer, and siRNA was added 
at a 3.6:1 (w/w) ratio.
In situ-forming gel preparation
In situ-forming gel containing 23% w/w poloxamer and 
0.25% w/w carbopol (PxCBP) was prepared as stated by 
Jones et al.31 Briefly, the required mass of each polymer was 
dissolved in distilled water (at 4°C) and proper quantities of 
propylene glycol and glycerol were added up to a 0.85% w/w 
final concentration each. The mixture was stirred in an Ultra-
Turrax® (IKA® T10 basic; San Pablo, Brazil), the pH was 
adjusted to 5.5 with triethanolamine, and the mixture was 
stored at 4°C prior to further use.
In situ-forming gel containing 23% w/w poloxamer and 1% 
w/w chitosan (PxChi) was prepared as stated by Gratieri et al.32 
Firstly, 30% w/w poloxamer solution was prepared by dissolv-
ing the required amount of poloxamer in distilled water (at 4°C) 
under agitation in Ultra-Turrax. The solution was stored at 4°C 
prior to further use. A 4% chitosan solution was prepared by 
dissolving the required amount of chitosan in 0.1% w/v acetic 
acid under agitation and the pH was adjusted to 5.5 with NaOH. 
Then, 23 mL of this chitosan solution was added to 77 mL of 
poloxamer solution (at 4°C), glutaraldehyde was added up to 
0.25% w/w, and the mixture was stirred in Ultra-Turrax and 
stored at 4°C prior to further use.
In situ-forming gels containing siRNA dendriplexes 
or siRNA lipoplexes were obtained by adding 50 µL of 
the complexes to 1500 µL of in situ-forming gels at 4°C, 
where the final concentrations were 0.47 nmol/mL siRNA, 
0.36 nmol/mL G7, and 0.65 µg/mL Lipofectamine 2000.
Rheological characterization  
of in situ-forming gels
Rheological studies were performed with an AR-G2 
  controlled stress rheometer (TA Instruments, New 
  Castle, DE) equipped with cone/plate geometry of 40 mm 
  diameter and an angle of 2°. Measurements were done on 
in   situ-forming gels without or with dendriplexes. Samples 
were carefully applied to the lower plate of the rheometer 
and allowed to equilibrate for at least 5 minutes prior to 
analysis. Each preparation was tested three times.
Measurement of gelation temperature
The gelation temperatures (Tsol/gel) of in situ-forming gels 
were measured using oscillatory rheometry as previously 
reported.33 The samples were subjected to a constant shear 
stress value and frequency (chosen in the linear viscoelas-
tic region, previously determined as 1 Pa and 3.14 rad/s, 
respectively). The temperature was increased in a stepwise 
manner from 4°C to 36°C (heating rate: 1°C/minute) and 
the elastic modulus (G′) was measured. The phase transition 
from liquid to gel (Tsol/gel) was inferred from the inflexion 
point of G′.
Measurement of flow properties
The flow curves of in situ-forming gels were determined at 
10°C and 25°C over a range of shear rates (0.1–100 1/s). 
The flow curves were modeled using the Oswald-de-Waele 
equation (power law)34 τ = kγ  n, where τ is the shear stress 
(Pa), k is the consistency index ((Pa s)n), γ is the rate of shear 
(1/s), and n is the flow behavior index (dimensionless). n is a 
measurement of the deviation from the Newtonian behavior, 
if n = 1 this indicates Newtonian behavior.
Measurement of viscoelastic properties
The frequency of samples subjected to a constant temperature 
of 10°C or 25°C and shear stress value (1 Pa) was increased 
in a stepwise manner from 0.1 to 100 rad/s and the elastic 
modulus (G′) and viscous modulus (G″) were measured.
Radiolabeling and purification
SiRNA was [32P] end-labeled using T4 polynucleotide kinase 
with 12.5 µM siRNA and 1.25 µM γ-[32P]ATP (50 µCi) as 
described previously35 and purified using Micro Bio-Spin 
P6 chromatography columns (Bio-Rad, Philadelphia, PA). 
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In order to remove traces of free γ-[32P]ATP, the purification 
was repeated three times until scintillation counting of the 
radioactivity in the mixture remained constant before and 
after the spin column, thus indicating the complete absence 
of free γ-[32P]ATP. The radiolabeling efficiency and purity 
of the [32P]-siRNA was checked by electrophoresis in 20% 
polyacrylamide gel in TBE buffer (0.089 M Tris base, 
0.089 M boric acid, 2 mM ethylenediaminetetraacetic acid) 
pH 8.3. The gel was cut horizontally in the middle and 
vertically between each lane, to determine the radioactivity 
corresponding to [32P]-siRNA (upper part of the gel lane) and 
[γ-32P]-ATP (lower part of the gel lane). Each fragment was 
disintegrated mechanically, scintillation solution was added 
and radioactivity was measured by liquid scintillation using a 
Wallac 1214 liquid scintillation counter (PerkinElmer).
The purity was calculated according to the   following 
  formula: [dpm [32P]-siRNA/(dpm [32P]-siRNA + dpm [γ-32P]-
ATP)] × 100, where dpm [32P]-siRNA are disintegra-
tions per minute (dpm) of the upper part of the gel lane 
and dpm [γ-32P]-ATP are the dpm of the lower part of the gel 
lane. The efficiency was calculated in the same way except 
that the aliquot submitted to electrophoresis was not purified. 
[32P]-siRNA was obtained with 70% of efficiency, 90%–95% 
of purity, and 50% of recovery.
Stability upon 100-fold dilution of [32P]-siRNA 
d  endriplexes in Tris-HCl buffer was determined by poly-
acrylamide gel electrophoresis. Ten minutes after dilution, 
samples were run in a 20% polyacrylamide gel in TBE 
buffer pH 8.3. The gel was cut as stated above and siRNA 
released from dendriplexes was calculated as: [dpm [32P]-
siRNA/(dpm [32P]-siRNA/G7 + dpm [32P]-siRNA)] × 100, 
where dpm [32P]-siRNA are the dpm of the lower part of the 
gel lane and dpm [32P]-siRNA/G7 are dpm of the upper part 
of the gel lane.
In vitro release from in situ-forming gels
The radioactivity release from the in situ-forming gels 
containing naked [32P]-siRNA, [32P]-siRNA dendriplexes, 
or [32P]-siRNA lipoplexes was determined using 3-µm 
pore size polycarbonate membrane Transwell® systems 
(Costar®, Corning Incorporated, Corning, NY). 0.5 mL of 
the in situ-forming gels at 4°C were placed in the upper 
chambers, placed in 24-well plates and incubated at 35°C for 
10 minutes. Then 1 mL of simulated nasal electrolyte solu-
tion (0.8 g/L NaCl, 3 g/L KCl, and 0.45 g/L CaCl2, pH 6.8)36 
was added to the lower chambers and the plates were placed 
into an oven at 35°C. At predetermined time points aliquot 
of 10 µL was taken from of the lower chambers, was mixed 
with 1.5 mL of scintillation cocktail, and the simulated nasal 
electrolyte solution was refilled. Radioactivity in each ali-
quot was determined using a Beckman LS 6000 scintillation 
counter (Pegasus Scientific, Rockville, MD), set to 1 minute 
counting time. The percentage of radioactivity release was 
calculated as follows = (dpma × 100) / dpmi × 100), where 
dpma are dpm of each time point lower chamber aliquot and 
dpmi are dpm in the upper chamber at the beginning.
Then, the silencing activity of the released material from 
in situ PxCBP forming gel containing siRNA dendriplexes 
in culture medium (Dulbecco’s modified Eagle’s medium; 
Gibco) was tested after 150 minutes of incubation, on 
enhanced green fluorescent protein-expressing J774 cells and 
compared with the silencing activity of siRNA dendriplexes 
not incorporated in gels, as previously described in Perez 
et al 2009 and 2011.28,30
Animals
Male Sprague-Dawley rats (8–10 weeks, ≈300 g) were pur-
chased from Facultad de Veterinaria, Universidad de Buenos 
Aires and housed in a temperature- and humidity-controlled 
room with a 12-hour light/dark cycle, with free access to food 
and water. All animals used in this study were maintained in 
accordance with the Guide for the Care and Use of Labora-
tory Animals (NIH Publication No. 85-23, revised 1996). 
The protocol was approved by the Ethics Committee of the 
Cardiovascular Research Center, National Research Council 
(CCT-La Plata CONICET, Argentina).
histopathology of nasal tissues  
after repeat administration
Animals were anesthetized by intraperitoneal injection of 
a mixture of ketamina and acepromazine at a dose of 45 
and 0.5 mg/kg, respectively, and dendriplexes in   Tris-HCl 
  buffer or within in situ-forming PxCBP gel were admin-
istered into the nostrils once a day for 3 consecutive days. 
Animals were placed in the supine position and a total 
volume of 60 µL (30 µL to each nostril in aliquots of 10 µL 
using a p10 micropipette) was administered. Control groups 
received three doses of Tris-HCl buffer or one dose of 0.1% 
w/v sodium dodecyl sulfate. Three hours after the last 
dose, the animals were sacrificed by cervical dislocation, 
and the heads were removed and fixed in Bouin solution 
for 24 hours followed by immersion in 70% v/v ethanol. 
After fixation, the heads were   decalcified for 4 days in a 
solution of formaldehyde/formic acid. Next, the heads were 
embedded in paraffin and sectioned in four 2–3 mm thick 
sections according to Jansson et al.37 Then, 5 µm-thick 
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cross-sections of sections containing respiratory and 
olfactory epithelium were made. Sections were mounted 
on cut edge glass slides and stained with hematoxylin and 
eosin or hematoxylin and periodic acid–Schiff reaction 
for microscopic examination. Toxicological evaluation 
was done by a trained toxicologist using the criteria of 
histopathology described by Bindseil et al.38 The presence 
of epithelial eosinophilia, luminal exudates, and leukocytic 
margination (inflammation signs), desquamated epithelial 
cells, hyperemia (excess of blood), and osteoblast activation 
(inflammation signs) was examined. The microscopic find-
ings were graded between 0 and 3 (0 = absent, + = minimal, 
++ = moderate, +++ = severe histological change).
Nasal absorption and brain distribution
Groups of male Sprague-Dawley rats (n = 3 per group) were 
anesthetized as stated above and then received intravenously 
or intranasally 28 pmol [32P]-siRNA (22 pmol G7 or 1.4 µg 
Lipofectamine 2000) corresponding to 10 µCi per dose per 
animal, as shown in Table 1. After 90 or 180 minutes, rats 
were euthanized and samples of blood and brains were col-
lected, washed with cold saline, blotted dry, and their weight 
determined. For scintillation counting, blood and tissue 
samples were dissolved in 0.5 mL benzethonium hydroxide 
at 37°C, sonicated for 30 minutes, and incubated overnight 
at 37°C. Then, 100 µL of 100 vol H2O2, 40 µL of 1 M HCl, 
and 5 mL of scintillation cocktail was added to each sample. 
The activity of [32P] in each sample was determined using 
a Beckman LS6000 scintillation counter, set to 1 minute 
counting time. The activity of the injected dose was calcu-
lated based on the scintillation count of a small sample of 
the injected solution.
Statistical analysis
Statistical analyses were performed by one-way analysis of 
variance, followed by Dunnett’s test using Prisma software 
(v 4.00; Graphpad Software Corporation, San Diego, CA). 
Significance levels are shown in the Figure legends.
Results and discussion
In situ-forming gels
The aim of the present work was to explore the intra-
nasal administration of siRNA dendriplexes within in 
situ-forming mucoadhesive gel as a means to increase 
brain   radioactivity. For this, an in situ-forming gel 
was prepared by blending a thermosensitive polymer 
with mucoadhesive agents.   Poloxamers, thermosensi-
tive amphiphilic block copolymers of poly (ethylene 
oxide)–poly (propylene oxide)–poly   (ethylene oxide) 
(PEO–PPO–PEO) are free-flowing liquids at room tem-
perature that allow easily reproducible administration 
into the nose. Once on the mucosa and in response to physi-
ological temperatures, Tsol/gel is undergone.31,32,39,40 The 
Tsol/gel is inversely proportional to poloxamer concen-
tration and for 15%–23% w/w solutions is close to body 
temperature (20ºC–30ºC).31,41 Poloxamer gels, however, 
have weak mechanical strength and are not mucoadhe-
sive.42 On the other hand, chitosan7,43 and carbopol44 form 
highly viscous concentrated mucoadhesive solutions. This 
makes application difficult and impairs the accuracy and 
reproducibility of the dosing volume. However, the litera-
ture indicates that mixtures of carbopol at 0.10%–0.25% 
w/w or chitosan at 0.5%–1.5% w/w with poloxamer, lead 
to liquid solutions of low viscosity and easy application at 
room temperature.31,32 The solutions become mucoadhesive 
gels within the nose, increasing the time of residence of the 
loaded material.
As mentioned above, a gel intended for nasal delivery has 
to possess mechanical properties other than   mucoadhesivity. 
The viscosity or consistency of the liquid has to be low 
enough to ensure ease of administration. The viscosity of the 
gel phase, on the other hand, has to be similar to that of mucus 
Table 1 Samples, dosage, routes and number of doses used in the different experimental groups
Experimental group Formulation Route of administration Number of dosesa Timeb (minutes)
siRNA/g7 Buffer Intravenous 1 90
siRNA/g7 Buffer Intranasal 1 90
siRNA/g7 Buffer Intranasal 2 180
siRNA/Lipofectamine™ 2000 Buffer Intranasal 2 180
siRNA/g7 PxCBP Intranasal 1 90
siRNA/g7 PxCBP Intranasal 2 180
siRNA/Lipofectamine 2000 PxCBP Intranasal 2 180
Naked siRNA PxCBP Intranasal 2 180
Notes: aThe two doses were administered with a 90-minute interval; btime between first administration and sacrifice.
Abbreviations: siRNA, small interfering RNA; g7, generation 7 dendrimers; PxCBP, poloxamer/carbopol gel.
submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1377
Intranasal 32P-siRNA dendriplexes in gelsInternational Journal of Nanomedicine 2012:7
in physiological conditions. Mucus is a non-Newtonian gel. 
At low shear rates, it is an elastic solid capable of recovering 
its original shape, while at high shear rates is a viscous liquid 
that can be irreversibly deformed. The viscosity of the nasal 
mucus ranges between 46, 5, and 1.3 Pa.s at shear frequen-
cies of 1, 50, and 100 rad/s, respectively.45 A mucoadhesive 
gel of a viscosity higher than that of mucus could not be 
removed by the waving movement of cilia; it would remain 
at the administration site for long periods, leading to infec-
tious and inflammatory processes.46 On the other hand, a 
mucoadhesive gel of low apparent viscosity would drain 
from the site of administration. Finally, the elastic properties 
of a gel have to predominate over its viscous properties to 
allow for its deformation but at the same time to impair its 
breaking by ciliary beating. Cilia beat at 1000 strokes per 
minute (around 17 Hz) and the elastic modulus of the mucus 
is 1 Pa, high enough to be removed by mucociliary clearance 
without being broken.
The Tsol/gel of each formulation was determined from 
the inflexion point of the elastic modulus G′ (a parameter 
measuring the material’s tendency to recover its original 
shape   following a stress-induced deformation), as a function 
of temperature. Our results showed that the Tsol/gel of PxChi 
was 23°C while that of PxCBP was 19°C. The addition of 
dendriplexes neither modified the curve shape nor the Tsol/
gel of PxChi but increased by 4°C the Tsol/gel of PxCBP 
(Figure 1).
At 10°C, PxCBP exhibited a Newtonian flow (Figure 2A) 
and viscoelastic behavior typical of liquids. Its viscous 
modulus G″ (a parameter measuring the extent to which 
the material resists the tendency to flow), increased as a 
function of the oscillation frequency, and was higher than G′ 
(Figure 3A). In contrast, PxChi exhibited a non-Newtonian 
pseudoplastic or shear thinning behavior (Figure 2A). The 
similar values of G″ and G′ indicated that PxChi pos-
sessed both viscous properties typical of liquids and the 
elastic   properties of solids (Figure 3A). Flow curves were 
adjusted to the power law model and the flow behavior 
(n) and consistency (k) indexes of each formulation were 
derived (Table 2). As expected, PxCBP had a flow index 
close to 1 and its viscosity was 0.25 Pa.s, whereas PxChi 
had a flow index lower than 1 and consistency higher than 
that of PxCBP. The addition of dendriplexes did not modify 
these properties.
At 25°C, both PxCBP and PxChi gels exhibited non-
Newtonian pseudoplastic behavior, with flow index lower 
than 1 and high consistency (Figure 2B, Table 2). The 
addition of dendriplexes to PxChi caused a decrease in 
shear stress at shear rates above 40 1/s, this indicating a 
permanent damage in the gel structure. On the contrary, 
the addition of dendriplexes to PxCBP did not modify the 
shape of the curves and the calculated ηapp was 5 and 2.5 Pa.s 
at shear rates of 50 1/s and 100 1/s, respectively. The two 
gels presented high elastic modulus (G′ 1.104 Pa) and low 
viscous modulus (G″ , 102–103 Pa, data not shown) that 
remained constant up to a frequency of 100 rad/s (16 Hz) 
(Figure 3B).
Before being removed by ciliary beating, the gel’s mesh 
has to release the dendriplexes within a short time period. 
This was estimated in two ways. In the first, the   radioactivity 
release when  32P-siRNA dendriplexes were incorporated 
within PxChi or PxCBP gels was determined. We observed 
that nearly 35% of the radioactivity was released from the 
PxCBP gel. A comparable amount of radioactivity was 
released from gels containing naked 32P-siRNA, while 55% 
of the radioactivity from gels containing free 32P-ATP was 
released after 150 minutes (Figure 4A). In contrast, there 
was no significant radioactivity release from PxChi gel 
during the same period of time (Figure 4B). Additionally 
the radioactivity released from PxCBP and PxChi gels 
containing 32P-siRNA lipoplexes was nearly 35% and 0%, 
respectively. Two of the primary mechanisms of drug reten-
tion are physical hindrance caused by the network of gel 
matrix and possible attractive forces between the drug and 
the polymer molecules.29 PxChi gel had a higher consistency 
index (higher viscosity) than the PxCBP gel that together 
with its positive charge could contribute to the higher 
retention within the mesh. In the second, we determined 
the silencing activity of the material released from PxCBP 
gel containing siRNA dendriplexes on enhanced green 
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Figure 1 Variations of the elastic modulus, g′, as a function of temperature for the 
in situ-forming gels with or without dendriplexes.
Abbreviations: PxCBP, poloxamer/carbopol gel; PxChi, poloxamer/chitosan gel.
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fluorescent protein-expressing J774 cells. We found that 
the silencing caused by the released material was nearly 
50% of that produced by siRNA dendriplexes in buffer. In 
view of the absence of cell internalization and therefore 
lack of silencing activity of naked siRNA,28 these results 
suggested that at least part of the released material was 
dendriplexes.
Overall, these results showed that the Tsol/gel of both 
in situ-forming gels containing dendriplexes was suit-
able for nasal administration. However, while the PxChi 
liquid showed a non-Newtonian pseudoplastic behavior 
of high consistency (apparent viscosity) and difficult 
  manipulation, the PxCBP liquid had a Newtonian behavior 
of low viscosity and easy manipulation. In the gel phase 
both formulations showed apparent viscosity similar 
to that of the mucus at low shear rates but higher than 
those of an aqueous solution (0.5 Pa.s). The irreversible 
deformation of PxChi gel at shear rate above 40 1/s and 
the nonrelease of radioactivity led us to discard this gel 
for further in vivo assays. 
Assessment of local toxicity
Intranasal administration of dendriplexes can cause 
local irritation, epithelial or subepithelial toxicity, and 
ciliatoxicity. Histopathological screening of the rat 
nasal mucosa showed no important alterations after 
three doses of dendriplexes in buffer or within the gel 
(Figure 5A–F). On the contrary, the mucosa treated with 
SDS showed moderate and severe lesions (Table 3). In 
spite of the absence of similar reports in the literature, 
it was recently determined that 120 minutes after treat-
ment with 0.1% to 5% w/v poly(amidoamine) dendrimers 
0–3 generation, release of proteins and lactate dehydroge-
nase enzyme in the lavage of the nasal cavity was insig-
nificant, as compared to that induced by sodium dodecyl   
sulfate.47
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Nasal absorption and brain distribution
After intranasal administration of [32P]-siRNA dendriplexes 
within in situ-forming mucoadhesive PxCBP gels, we found 
that part of the radioactivity was absorbed across the nasal 
mucosa, an important fraction was swallowed and aspirated 
(resulting in radioactivity in the esophagus and trachea) 
while a minimal fraction could have accessed the brain 
parenchyma.
The radioactivity in blood after one or two doses of intra-
nasal dendriplexes in buffer or gel, or naked siRNA in gel, 
was around 0.01–0.02 µCi/mL (0.1% of the injected dose 
[ID]). The same was found 90 minutes after the administra-
tion of intravenous dendriplexes (Figure 6A). Interestingly, 
gel electrophoresis analysis of the stability of dendriplexes 
after dilution showed that nearly 85% were disassembled 
after a 100-fold dilution. Therefore, since intravenously 
injected dendriplexes were submitted to a 250-fold dilution, 
the radioactivity in blood would correspond to that of naked 
siRNA or to its fragments. In this setting, our results were 
in agreement with those of van de Water et al,48 and Gao 
et al,49 where intravenously administered naked siRNA is 
rapidly eliminated by the kidneys, less than 0.1% of the ID 
remained in the rats’ blood after 1 hour. Similarly, the 0.1% 
ID in blood after intranasal administration would correspond 
to naked siRNA (because of the dilution suffered when 
entering the blood after mucosal absorption). Recently, Han 
et al,50 also reported that pDNAs up to 14.1 kb in size can be 
systemically absorbed after intranasal administration with a 
Tmax of 90 minutes.
Intranasal naked siRNA within gel and intravenous den-
driplexes delivered similar amounts of radioactivity to the 
brain (Figure 6B). However, intranasal dendriplexes both 
in gel and in buffer delivered significantly higher amounts 
of radioactivity to the brain than by the intravenous route. 
Moreover, the amounts of radioactivity in the brain after a 
single dose in buffer or in gel were comparable, but after 
a second dose of dendriplexes in buffer, the amount of 
radioactivity did not increase. Remarkably, a second dose 
in gel not only increased by 3.5-fold the amount of radioac-
tivity in brain as compared to the first dose, but by twofold 
the delivered by dendriplexes in buffer.   Additionally, the 
second dose of dendriplexes in gel delivered eightfold the 
amount of radioactivity in the brain than that delivered by 
two doses of naked siRNA in gel. Previously we deter-
mined that siRNA dendriplexes are taken up by caveolin 
and by caveolin- and clathrin-mediated endocytosis by 
glioblastoma cells and macrophages respectively; naked 
siRNA however is not taken up by any of these cell 
types.30 The lack of cellular uptake of naked siRNA could 
be the reason for its low level of brain radioactivity. The 
mediation of a direct brain delivery mechanism for naked 
siRNA could be discarded. On the other hand, two doses of 
lipoplexes in gels delivered lower amounts of radioactivity 
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Figure 3 Elastic (g′) and viscous (g″) modulus as a function of angular frequency of 
in situ-forming gels with or without dendriplexes at (A) 10°C and (B) 25°C.
Abbreviations: PxCBP, poloxamer/carbopol gel; PxChi, poloxamer/chitosan gel.
Table 2 Parameters obtained from flow curves modeled using 
the Oswald-de-Waele equation (power law) of in situ-forming 
gels at 10°C and 25°C
Sample Temperature  
(°C)
Flow  
index  
(n)
Consistency  
index  
(k: Pa.sn)
R2
PxCBP 10 0.929 0.25 0.99
PxCBP/dendriplex 10 0.901 0.24 0.99
PxChi 10 0.201 55 0.98
PxChi/dendriplex 10 0.373 10 0.97
PxCBP 25 0.063 318 0.99
PxCBP/dendriplex 25 0.043 209 0.92
PxChi 25 0.059 351 0.70
PxChi/dendriplex 25 0.074 263 0.63
Abbreviations: PxCBP, poloxamer/carbopol gel; PxChi, poloxamer/chitosan gel.
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than two doses of lipoplexes in buffer. Clearly, in spite of 
finding that in vitro the radioactivities were released from 
the gel at the same rate, in vivo the delivery of radioactivity 
to the brain was higher from gels containing dendriplexes 
than when containing lipoplexes. Dendriplexes and lipo-
plexes share a size order of 150 nm. Shape and surface 
characteristics such as Z potential (25 mV dendriplexes vs 
46.6 mV lipoplexes), or a potential release of naked siRNA 
from gels containing lipoplexes could explain the in vivo 
differences.8
The brain/blood radioactivity ratio is a critical para  meter 
to assess direct delivery to the parenchyma, since the radioac-
tivity in the brain is the sum of that in parenchyma plus that in 
the brain blood.51 After two doses of intranasal dendriplexes 
in gel the brain/blood ratio was twofold higher than after 
intranasal dendriplexes in buffer and nearly fivefold higher 
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Figure 4 Release profile of radioactivity from in situ-forming (A) poloxamer/carbopol and (B) poloxamer/chitosan gels as function of time.
Abbreviations: PxCBP, poloxamer/carbopol gel; PxChi, poloxamer/chitosan gel; siRNA, short interference RNA; ATP, adenosine 5″-triphosphate.
Figure 5 histopathology of rat nasal tissues after three intranasal doses of (A–C) dendriplexes in buffer or (D–F) dendriplexes within in situ-forming poloxamer/carbopol 
gel. (A and D) magnification ×40, (B and E) magnification ×100, (C and F) magnification ×400 (respiratory epithelium). Arrows showed luminal exudates (A and E) and 
normal lymphatic infiltration (E).
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Figure 6 Scintillation measurement of radioactivity in (A) blood and (B) brain after one or two intravenous or intranasal doses of dendriplexes in rats (n = 3).
Notes: *P , 0.05; **P , 0.01 (statistically significant difference).
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Table 3 histopathological evaluation of nasal mucosa after treatments
Buffer Dendriplex in buffer Dendriplex within PxCBP gel SDS
Epithelial eosinophilia 0 0 0 0
Leukocytic margination 0 0 0 +
Luminal exudate ++ + ++ +++
Desquamated epithelial cells 0 0 0 +
hyperemia + 0 + ++
Osteoblast activation 0 0 0 +
Notes: The microscopic findings were graded between 0 and 3 (0 = absent, + = minimal, ++ = moderate, +++ = severe histological change).
Abbreviations: PxCBP, poloxamer/carbopol gel; SDS, sodium dodecyl sulfate.
than after intranasal naked siRNA in gel and than intravenous 
dendriplex administrations (Figure 7A).
We found as well that two doses of intranasal dend-
riplexes in gel delivered a significantly higher level of 
radioactivity in the olfactory bulb and hypothalamus than 
after intravenous or intranasal-in-buffer administrations 
(  Figure 7B). The material delivered to these target tissues 
could be further distributed to distant zones of the CNS. 
Indeed, a number of studies have shown that after a primary 
accumulation of particulate material in the olfactory bulb, 
small enough particles could be transported via axons 
through the olfactory bulb into the olfactory cortex and 
then to the caudal pole of the cerebral hemisphere and into 
the cerebrum and the cerebellum.52–54 Probably the in situ-
forming mucoadhesive gels maintain the structural stability 
of dendriplexes better than the liquid nonmucoadhesive 
buffer. Hence, opportunities for dendriplexes to be taken 
up by olfactory neurons would be higher for dendriplexes 
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within gel than in buffer. Curiously, 180 minutes after two 
intranasal doses of lipoplexes in gels, the olfactory bulb 
showed no radioactivity, and there was only weak activity 
in the   hypothalamus. Variations in the transcellular pathway 
(apical to basolateral transport through epithelial cells) fol-
lowed in nose-to-brain delivery between dendriplexes and 
lipoplexes could explain this difference.
In general, the low concentrations of drugs found in the 
brain compared to other organs (often below 0.5% and can 
be as low as 0.01% ID/g brain) are nonetheless sufficient 
to result in a therapeutic effect.55 After two intranasal doses 
of dendriplexes within gel, the drainage to lungs and to the 
gastrointestinal system was not impaired (data not shown); 
however, we found 0.18% ID/g brain. Han et al,50 found 
0.01% ID/g brain 60 minutes after an intranasal dose of 
pDNA. Also we found higher %ID/g brain than that obtained 
by Huang et al,56,57 (0.08–0.14%ID/g brain) who used intra-
venous administration of pDNA complexed with transferrin- 
or lactoferrin-conjugated PEG-modified poly(amidoamine) 
dendrimers, but without covalent modification and with 
reduced systemic delivery.
In the current experimental design, the finding of radio-
activity in the brain does not lead us to assume the presence 
of intact siRNA molecules or siRNA dendriplexes. However, 
this is the first work showing that the intranasal administration 
of in situ-forming mucoadhesive gel containing (nontargeted) 
siRNA dendriplexes increases the direct brain delivery of 
radiolabel above that achieved by parenteral administration 
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Figure 7 (A) Brain/blood radioactivity ratio and (B) brain distribution of radioactivity following one or two intravenous or intranasal doses of dendriplexes in rats.
Note: *P , 0.05 (statistically significant difference).
Abbreviations: IV, intravenous; DX, dendriplex; LX, lipoplex; siRNA, short interference RNA; PxCBP, poloxamer/carbopol gel.
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of dendriplexes. Further studies will analyze the silencing 
activity of dendriplexes in vivo.
Conclusion
32P-siRNA complexation with dendrimers, incorporation 
of the dendriplexes into PxCBP gel, and administration of 
two intranasal doses were necessary to achieve higher brain 
radioactivity than that achived by intravenous dendriplexes or 
intranasal naked siRNA. The increased radioactivity within 
the olfactory bulb suggested that the combination abovemen-
tioned favors the mediation of a direct brain delivery.
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